Alpha Tau Medical Ltd
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Alpha Tau Medical Ltd. Alpha Tau Medical Ltd. (NASDAQ: DRTS), a clinical-stage oncology therapeutics company headquartered in Jerusalem, Israel, and founded in 2016, develops and seeks to commercialize its proprietary Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid tumors. Alpha DaRT utilizes interstitial radioactive sources, primarily based on radium-224, that release short-lived alpha-emitting atoms to deliver highly potent, localized radiation over several millimeters, enabling conformal treatment of tumors while sparing surrounding healthy tissue; the technology targets localized unresectable, refractory or recurrent tumors previously treated with surgery or conventional radiation, cancers with high unmet needs such as pancreatic adenocarcinoma and glioblastoma, and metastatic tumors in combination with systemic therapies including immunotherapies. The company conducts clinical trials for skin cancer (recurrent cutaneous squamous cell carcinoma), oral cavity cancer, pancreatic cancer, prostate cancer, lung cancer, liver cancer, breast cancer, and glioblastoma multiforme, with preclinical studies for brain and other cancers; operations span Israel, the United States, and global clinical sites in collaboration with leading cancer centers and institutions. Recent developments include the successful treatment of the first patient in its U.S. multi-center pilot study for pancreatic cancer, receipt of a radioactive material license for its New Hampshire commercial-scale manufacturing facility to support Alpha DaRT production starting in 2026, FDA approval of an Investigational Device Exemption for a U.S. pilot study in recurrent glioblastoma multiforme, ongoing patient recruitment in the U.S. pivotal ReSTART trial for skin cancer, and participation in major investor conferences such as the Jefferies Global Healthcare Conference; as of Q3 2025, Alpha Tau reports a cash balance of $75.9 million to fund these advancements toward commercialization.
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
New Strong Sell Stocks for July 7th
New Strong Sell Stocks for July 2nd
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
Alpha Tau Medical: A Lot Of Shots On Goal
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau to Participate in May Investor Conferences
Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute